EUVIMEDEUVIMED entdecken
Kohortenstudie

The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study

Ali Aytaç, Bilgin Demir, Kübra Canaslan, Halil İbrahim Ellez, Yasemin Aydınalp Camadan

Journal of Current Hematology & Oncology Research · 08.08.2026 · 4 (3) · 86-92

DOI: 10.51271/jchor-0088 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 08.08.2026. Verfasst von Ali Aytaç und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The Advanced Lung Cancer Inflammation Index (ALI)—calculated from body mass index (BMI), serum albumin, and neutrophil-to-lymphocyte ratio (NLR)—is an accessible composite biomarker of systemic inflammation and nutritional status. Its prognostic value in second-line immune checkpoint inhibitor (ICI) therapy in an ICI-naive population remains undefined.

Methods

This multicenter retrospective cohort study included 249 metastatic non-small cell lung cancer (NSCLC) patients treated with second-line single-agent nivolumab without prior immunotherapy exposure. ALI was categorized using a receiver operating characteristic (ROC)-derived cut-off of 27.27. Treatment response was assessed by RECIST 1.1. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox regression models.

Results

High baseline ALI (>=27.27) was associated with significantly longer median PFS (10.05 vs. 6.01 months; p=0.012) and OS (13.89 vs. 6.27 months; p

Zitieren

APA

Aytaç, A., Demir, B., Canaslan, K., Ellez, H. İ., & Camadan, Y. A. (2026). The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study. Journal of Current Hematology & Oncology Research, 4(3), 86-92. https://doi.org/10.51271/jchor-0088

Vancouver

Aytaç A, Demir B, Canaslan K, Ellez Hİ, Camadan YA. The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study. Journal of Current Hematology & Oncology Research. 2026;4(3):86-92. doi:10.51271/jchor-0088

BibTeX
@article{Ayta2026,
  author = {Aytaç, Ali and Demir, Bilgin and Canaslan, Kübra and Ellez, Halil İbrahim and Camadan, Yasemin Aydınalp},
  title = {The predictive and prognostic value of the Advanced Lung Cancer Inflammation Index in metastatic NSCLC receiving second-line nivolumab: a multicenter retrospective cohort study},
  journal = {Journal of Current Hematology & Oncology Research},
  year = {2026},
  volume = {4},
  number = {3},
  pages = {86--92},
  doi = {10.51271/jchor-0088}
}
Kostenlos starten →